The updated workflow approval suggests “that direct imaging guidance, such as ultrasound, may be used as an alternative to fluoroscopy,” the release states.
The change in labeling that has now been approved by the FDA “improves safety, and efficiency of cardiac ablation procedures,” Jasmina Brooks, president of Biosense Webster said in a statement. “As a result of this update, our teams can now proactively discuss the fluoroscopy alternative workflow with our customers to reinforce the benefits of the Biosense Webster portfolio of products.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
